We develop novel treatments and inventions where there is no treatment or diagnostic tool available. It is an exciting place to be when you are breaking new scientific ground and encourages an incredible spirit of enthusiasm and commitment in all our research teams and partners.
Currently we develop products for cats and dogs across five key areas
While there have been strides in veterinary cardiac care, there are many areas of unmet need in veterinary cardiology. At TriviumVet we are focusing on addressing complex, chronic and challenging cardiac ailments in dogs and cats. We work with some of the veterinary world’s most esteemed researchers and academics in the field and have a number of products both in development and active in clinical trials.
Our lead cardiac product is a proprietary veterinary Rapamycin formulation. Evidence from peer-reviewed literature has demonstrated that Rapamycin improves markers of cardiac health and function in dogs and TriviumVet are spearheading the research of its use in cats.
For information on our cardiac clinical trials you can visit our clinical trials page here.
The veterinary field poses an inherent challenge when it comes to assessment of pain as our animals cannot communicate pain to us verbally. As a result, the TriviumVet team as part of the development of a novel neuropathic pain treatment have created a novel, copyrighted pain assessment tool which is used to measure effectiveness.
The first phase in this development has been completed over several months, and has been extremely successful, demonstrating that the tool is sensitive to the presence of the target indication, with affected dogs being clearly differentiated from health matched controls. This represents a major advancement in the ability to objectively assess patients with pain and other clinical signs attributed to chronic pain.
Gastrointestinal problems are one of the most common complaints for small animals in veterinary practice. TriviumVet has developed a veterinary PPI to treat gastric ulceration in dogs and which will be the first registered pharmaceutical treatment for GU in dogs.
The gut is the foundation of our health and immune system. Through our extensive gastroenterology research, TriviumVet has invented a patented device to determine GI permeability and which will be used to assess general well-being in addition to diagnosing GI disease.
Pets have become an important part of our lives and over time have become members of the family. They share our homes, our food and our environments; and while their lives are all too short when they leave us, their rapid aging relative to humans offers a unique key to unlocking many of the mysteries of how and why we age. Targeting and treating some of these chronic diseases of aging in our pets has the potential to not only be of benefit to them but also to humans suffering from the same diseases.
Our One Health approach is to develop anti-aging interventions that target specific diseases in companion animals and translate this research into the human field. This synergistic approach will improve the overall quality of life in humans, and our beloved pets as they age.
TriviumVet are delighted to be involved as a research collaborator with the Dog Aging Project, an innovative initiative that brings together a community of dogs, owners, veterinarians, researchers, and volunteers to carry out the most ambitious canine science project in the world. The Dog Aging Project is centered on two fundamental goals: understanding how genes, lifestyle and the environment influence aging and intervening to increase health span, the period of life spent free from disease.
Our patented veterinary Rapamycin (RapaVet) is being administered to a subset of the Dog Aging Project dogs to monitor its effect on age related decline. This study is called TRIAD and further details can be found below.
Chronic Kidney Disease is a significant issue in both human and cats and indicative of age-related decline in kidney function. The feline CKD study taking place at Ohio State University is assessing our proprietary Rapamycin formulation in CKD in cats. The results of this study will be an exciting milestone in understanding the disease and developing a new veterinary treatment.
TriviumVet are engaged with a network of research institutions focused on developing new therapeutics to combat diseases of aging. Our animal research lays the foundation for accelerating much of this research and further detail of our human collaborations will be announced later in 2022.
The Dog Aging Project is an innovative initiative based in the United States that brings together a community of dogs, owners, veterinarians, researchers, and volunteers to carry out the most ambitious canine health study in the world. The Dog Aging Project is funded by the National Institute on Aging, part of the National Institutes of Health. The team will follow tens of thousands of companion dogs for ten years to identify the biological and environmental factors that maximise healthy longevity.
The goal of the Dog Aging Project is to understand how genes, lifestyle, and environment influence aging. That information will then be used to help dogs and people increase health span, the period of life spent free from disease. A subset of participating dogs will be selected to be part of a new clinical study (TRIAD) to explore the potential of the drug Rapamycin to improve health span.Key Facts about
The aim of the Test of Rapamycin in Aging Dogs (TRIAD) is to conduct a double-blind, placebo-controlled clinical trial of a drug called Rapamycin. This study is a subset of the overall project that investigates the use of a drug (rapamycin) to potentially slow the aging process and prolong healthy life.Key Facts about